Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004–2013
- 27 December 2016
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 96 (3) , 373-381
Abstract
Myeloproliferative neoplasms (MPNs), with an expected increment in number, impose substantial economic and social burdens. To this end, we conducted a nationwide population-based descriptive epidemiology study. We also investigated medical cost associated with MPNs. Prevalence was the highest for essential thrombocythemia (ET) (range 4.1–9.0 per 100,000), followed by polycythemia vera (PV) (range 2.8–5.4 per 100,000) and primary myelofibrosis (PMF) (range 0.5–0.9 per 100,000). ET incurred the highest cumulative total cost at US$35 million and the most frequent hospital visits, while PMF incurred the highest average cost per person at US$5000. The mean hemoglobin level was 16.9 ± 2.2 g/dL for PV males and 15.5 ± 2.7 g/dL for PV females. Further analyses on hemoglobin levels showed the true positive rate of PV from the significantly elevated hemoglobin group (defined as >18.5 g/dL for men and >16.5 g/dL for women) was 3.01% and that of MPNs was 3.1%. Here, we provide the biggest population-based report on MPN epidemiology that can readily be used as a representative Asian data.Keywords
Funding Information
- National Health Insurance Service Ilsan Hospital Grant (NHIMC 2015-20-010)
This publication has 35 references indexed in Scilit:
- Social factors associated with centenarian rate (CR) in 32 OECD countriesBMC International Health and Human Rights, 2013
- Performance of Papanicolaou Testing and Detection of Cervical Carcinoma In Situ in Participants of Organized Cervical Cancer Screening in South KoreaPLOS ONE, 2012
- Introduction: Health of the Health Care System in KoreaSocial Work in Public Health, 2010
- Results of Colorectal Cancer Screening of the National Cancer Screening Program in Korea, 2008Cancer Research and Treatment, 2010
- Myeloproliferative disordersBlood, 2008
- Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programsBlood, 2008
- Essential thrombocythemia, polycythemia vera, and myelofibrosis: Current management and the prospect of targeted therapyAmerican Journal of Hematology, 2008
- Epidemiology of the Myeloproliferative Disorders Polycythemia Vera and Essential ThrombocythemiaSeminars in Thrombosis and Hemostasis, 2006
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- Trends in the incidence of polycythemia vera among olmsted county, Minnesota residents, 1935–1989American Journal of Hematology, 1994